The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma

Journal of International Medical Research

Volumn 38, Issue 1, 2010, Pages 111-126

  Zhang, Dong Wei ^a   Li, H L ^a   Yao, Q ^a   Yang, W L ^a   Wang, H L ^b   Zhai, D X ^a   Zhou, Z H ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Mudanjiang Second People's Hospital   (China)

Author keywords

Anti angiogenic drugs; Apoptosis; Colorectal carcinoma; Nude mouse model; Oxaliplatin; Recombinant human endostatin; Synergistic effect

Indexed keywords

ENDOSTATIN; OXALIPLATIN; OXALIPLATIN PLUS RECOMBINANT HUMAN ENDOSTATIN; RECOMBINANT HUMAN ENDOSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN; YH 16;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL STRUCTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ELECTRON MICROSCOPY; ERYTHEMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MICROSCOPY; MICROVASCULATURE; MICROVESSEL DENSITY; MOUSE; NICK END LABELING; NONHUMAN; PAPULE; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT;

EID: 77749277517     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800113     Document Type: Article

References (46)

1. Boyle P, Langman JS: ABC of colorectal cancer: epidemiology. BMJ 2000; 321: 805-808.
2. Tang X-Y, Zhu Y-Q, Tao W-H, et al: Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 2007; 83: 338-343.
3. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
4. Abdollahi A, Hahnfeldt P, Maercker C, et al: Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
5. Jin X, Bookstein R, Wills K, et al: Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther 2001; 8: 982-989.
6. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
7. Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
8. Brideau G, Makinen MJ, Elamaa H, et al: Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67: 11528-11535.
9. Sun Y, Wang J, Liu Y, et al: Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005; 23(suppl): 7138.
10. Simpson D, Dunn C, Curran M, et al: Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003; 63: 2127-2156.
11. Chou TC, Talalay P: Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
12. Chou TC, Motzer RJ, Tong Y, et al: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
13. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180.
14. Weidner N: Tumour vascularity and proliferation: clear evidence of a close relationship. J Pathol 1999; 189: 297-299.
15. Mattern J, Koomagi R, Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931-934.
16. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics. CA Cancer J Clin 2001; 51: 15-36.
17. 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009; 50(suppl 1): 43S-54S.
18. Gebbia V, Verderame F, Ferraù F, et al: Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. Ann Oncol 2006; 17(suppl 7): vii60-vii65.
19. Weinstat-Saslow D, Steeg PS: Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8: 401-407.
20. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
21. Folkman J: Endogenous angiogenesis inhibitors. APMIS 2004; 112: 496-507.
22. Dutour A, Monteil J, Paraf F, et al: Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 2005; 11: 311-319.
23. Yokoo S, Masuda S, Yonezawa A, et al: Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 2008; 36: 2299-2306.
24. Droz JP, Muracciole X, Mottet N, et al: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 2003; 14: 1291-1298.
25. Allen WL, Johnston PG: Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005; 23: 4545-4552.
26. Qin TJ, An GL, Zhao XH, et al: Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol 2009; 15: 871-876.
27. Black WR, Agner RC: Tumour regression after endostatin therapy. Nature 1998; 391: 450.
28. Boehle AS, Kurdow R, Schulze M, et al: Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 2001; 94: 420-428.
29. Drixler TA, Borel Rinkes IH, Ritchie ED, et al: Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000; 60: 1761-1765.
30. Chen M,Wang J: Initiator caspases in apoptosis signaling pathways. Apoptosis 2002; 7: 313-319.
31. Green DR: Apoptotic pathways: ten minutes to dead. Cell 2005; 121: 671-674.
32. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-542.
33. Collins MK, Lopez Rivas A: The control of apoptosis in mammalian cells. Trends Biochem Sci 1993; 18: 307-309.
34. Darzynkiewicz Z: Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J Cell Biochem 1995; 58: 151-159.
35. Yao Y, Zhao H, Sun Y, et al: Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer. Tohoku J Exp Med 2008; 215: 267-278.
36. Dhanabal M, Ramchandran R, Waterman MJ, et al: Endostatin induces endothelial cell apoptosis. J Biol Chem1999; 274: 11721-11726.
37. Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54: 17-28.
38. Dkhissi F, Lu H, Soria C, et al: Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997-1008.
39. French L: Dysmenorrhea. Am Fam Physician 2005; 71: 285-291.
40. Lee CH, Wu CL, Shiau AL: Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004; 6: 1382-1393.
41. Su SJ, Yeh TM, Chuang WJ, et al: The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 2005; 69: 307-318.
42. Yamanaka R, Tanaka R: Gene therapy of brain tumor with endostatin. Drugs Today (Barc) 2004; 40: 931-934.
43. Rehn M, Veikkola T, Kukk-Valdre E, et al: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98: 1024-1029.
44. Hellberg V, Wallin I, Eriksson S, et al: Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37-47.
45. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
46. te Velde EA, Vogten JM, Gebbink MF, et al: Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002; 89: 1302-1309.